Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS Burmester, G. R., Garg, A., Van Hoogstraten, H., Graham, N., Boddy, A., Parrino, J., Genovese, M. C. WILEY-BLACKWELL. 2016: 40–41
View details for Web of Science ID 000375046500119